So everyone's fist up in the air right now about Eli Lilly and those GLP-1 drugs they're pushing. Mounjaro and Zepbound are genuinely impressive products—the market data shows 99% and 175% revenue growth expected for 2025, which is pretty wild. These two alone make up over half of Eli Lilly's total revenue. Wall Street has absolutely gone nuts for this story.

But here's the thing that's been bothering me: the valuation is completely detached from reality. You're looking at a P/E of 44 with a dividend yield of just 0.6%. That's not investing, that's speculation dressed up as dividend income. The stock is priced for perfection, and there's zero margin for error if anything goes sideways with those two products.

Meanwhile, nobody's talking about Merck anymore, which is kind of interesting. They're not in the GLP-1 game at all—they're focused on cancer, infections, and cardiometabolic diseases. Yeah, maybe less sexy than weight loss drugs right now, but these are massive therapeutic markets that aren't going anywhere.

Here's where Merck actually makes sense: P/E of 16 versus Eli Lilly's 44. Dividend yield of 2.8% versus 0.6%. That's a massive difference. And they've got a solid payout ratio around 50%, so the dividend feels genuinely sustainable. Keytruda's got some patent concerns coming up in the U.S., but they've got international patents running into the early 2030s, plus a new delivery method that could push that even further.

The real story here isn't that Eli Lilly is bad—it's genuinely executing well. The story is that you're paying an insane premium for that execution. If you actually want dividend income from a pharma company, Merck gives you way more bang for your buck with a more reasonable valuation. Sometimes the best opportunity isn't the hottest story; it's the one everyone's sleeping on.